FDA Approves Furoscix ReadyFlow - Takeaways - MDSpire

FDA Approves Furoscix ReadyFlow

Clinical data demonstrated achievement of the primary pharmacokinetic endpoint, with urine output and sodium and potassium excretion comparable with those observed with intravenous furosemide, according to MannKind.

  • By

  • Kathryn Wighton

  • July 24, 2026

  • 3 min

Share

  • 1

    Furoscix ReadyFlow received FDA approval for treating edema in adults with heart failure or chronic kidney disease.

  • 2

    The product delivers furosemide via a subcutaneous autoinjector, completing administration in 10 seconds or less.

  • 3

    Clinical data showed that Furoscix ReadyFlow met its primary pharmacokinetic endpoint, providing IV-equivalent furosemide exposure.

  • 4

    The safety profile of Furoscix ReadyFlow aligns with known effects of oral and intravenous furosemide.

  • 5

    Common adverse events include administration-site reactions such as bruising, erythema, swelling, and pain.

Original Source(s)

FDA Approves Furoscix ReadyFlow

  • by Kathryn Wighton

  • July 24, 2026

Related Content

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.

Recognizing the Transition to Advanced Heart Failure Earlier

Despite major advances in guideline-directed medical therapy (GDMT), worsening heart failure continues to drive significant morbidity, repeat hospitalizations and healthcare utilization worldwide.

  • May 27, 2026

  • 6 min